Credit: Original article published here.
DocWire News Medical Lead Dr. Payal Kohli reviewed the REDUCE-IT trial, which demonstrated that icosapent ethyl intervention twice daily is superior to placebo in reducing triglycerides (TGs), cardiovascular events, as well as CV mortality in patients with high TGs and either known CVD or individuals with known CVD or at high risk for developing it, and patients on statin therapy with relatively well-controlled LDL levels. The study was presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with World Congress of Cardiology (ACC.23/WCC).
